Viridian Therapeutics Prepares for Transformational 2026

– Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track – – Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively – – … [Read more…]

Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, England & CHICAGO–(BUSINESS WIRE)–#BioTechNews–Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option … [Read more…]

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Study showed a statistically significant disease-free survival (DFS) benefit in all SignateraTM-positive patients following blinded central review AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium … [Read more…]

Reproductive Partners Medical Group Announces Westminster Clinic Expansion to New State of the Art Facility in Long Beach

LONG BEACH, Calif.–(BUSINESS WIRE)–Reproductive Partners Medical Group (RPMG), a nationally respected leader in fertility care and family building, announced the relocation of its Westminster fertility clinic to a newly designed, patient-focused facility complete with lab and surgery center in Long Beach, California. The move is designed to better serve patients across greater Los Angeles and … [Read more…]

Priority Life Care Selects ECP to Power an AI-Forward Clinical Transformation Across 60+ Communities

PLC partners with a modern, data-driven clinical platform to enhance resident care, streamline staff workflows, and support scalable growth MILWAUKEE–(BUSINESS WIRE)–#assistedliving—Priority Life Care (PLC), a senior living provider serving more than 4,000 residents across 60+ communities, today announced a major investment in its technology infrastructure through a new enterprise partnership with ECP. ECP is the … [Read more…]

Priority Health and Group Health Cooperative of Eau Claire Finalize Transaction to Expand Access to High-Quality Care

Priority Health becomes four-state health plan GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Priority Health, a Michigan-based health plan serving more than 1.3 million members, has completed a transaction with Group Health Cooperative of Eau Claire (the Cooperative), a community-based health plan in Wisconsin serving more than 61,000 members, that establishes Priority Health as the sole governing member of … [Read more…]

Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

BOSTON–(BUSINESS WIRE)–Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Daphne Zohar, Co-Founder and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:30 a.m. PST. Ms. Zohar will … [Read more…]

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs

BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#ADC—Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing … [Read more…]

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global … [Read more…]

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company … [Read more…]